Allspring Global Investments’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Allspring Global Investments's NBIX Position: Q2 2026 in Review
Allspring Global Investments reduced its Neurocrine Biosciences (NBIX) stake by 9.8% in Q2 2026, selling an estimated $4.85M and leaving 299,741 shares worth $50.3M. The position accounts for 0.08% of the portfolio, ranked #294.
Allspring Global Investments first reported a position in NBIX in Q4 2021 and has held it in 19 quarters since. The position peaked at $97.8M in Q2 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Allspring Global Investments held 299,741 shares of Neurocrine Biosciences worth $50.3M as of Q2 2026.
- Allspring Global Investments sold 32,667 Neurocrine Biosciences shares in Q2 2026, an estimated $4.85M.
- Neurocrine Biosciences made up 0.08% of Allspring Global Investments's portfolio in Q2 2026, its #294 holding.
- Allspring Global Investments first reported a position in Neurocrine Biosciences in Q4 2021 and has held it in 19 quarters since.
- Allspring Global Investments's Neurocrine Biosciences position peaked at $97.8M in Q2 2024.
- 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.